InSilicoMinds was featured in the Startup Zone at CPHI Frankfurt 2025, standing out as one of the only end-to-end in silico and AI-driven drug development companies amidst global pharmaceutical innovators. The stage reinforced the importance and urgency of the work at the intersection of science, computation, and regulatory innovation.
One of the most exciting takeaways was that the industry consensus has never been clearer. In silico approaches are now ubiquitous across product types, from biologics and biosimilars to complex generics, NCEs, and vaccines, driving consistent, transparent, regulator-aligned evidence end to end.
Across three days at the event, InSilicoMinds:
• Engaged with leading pharma and biotech organizations across the US, EU, UK, India, and the rest of the world.
• Discussed collaborative pathways with regulators and global policy leaders.
• Demonstrated how AI plus computational modeling and simulation (PBPK, PopPK, QSP, Virtual BE, IVIVR) work in tandem to build more robust, transparent, and regulator-ready in silico evidence.
• Strengthened existing partnerships and opened new, strategic pipelines.
• Shared case studies showcasing real-world regulatory and development impact. The momentum for Model-Integrated Evidence and AI-augmented clinical development is accelerating.
